Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia

S. Kristian Hill, James L. Reilly, Margret S H Harris, Tin Khine, John A. Sweeney

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cognitive enhancement has become an important target for drug therapies in schizophrenia. Treatment development in this area requires assessment approaches that are sensitive to procognitive effects of antipsychotic and adjunctive treatments. Ideally, new treatments will have translational characteristics for parallel human and animal research. Previous studies of antipsychotic effects on cognition have relied primarily on paper-and-pencil neuropsychological testing. No study has directly compared neurophysiological biomarkers and neuropsychological testing as strategies for assessing cognitive effects of antipsychotic treatment early in the course of schizophrenia. Antipsychotic-naive patients with schizophrenia were tested before treatment with risperidone and again 6 weeks later. Matched healthy participants were tested over a similar time period. Test-retest reliability, effect sizes of within-subject change, and multivariate/univariate analysis of variance were used to compare 3 neurophysiological tests (visually guided saccade, memory-guided saccade, and antisaccade) with neuropsychological tests covering 4 cognitive domains (executive function, attention, memory, and manual motor function). While both measurement approaches showed robust neurocognitive impairments in patients prior to risperidone treatment, oculomotor biomarkers were more sensitive to treatment-related effects on neurocognitive function than traditional neuropsychological measures. Further, unlike the pattern of modest generalized cognitive improvement suggested by neuropsychological measures, the oculomotor findings revealed a mixed pattern of beneficial and adverse treatment-related effects. These findings warrant further investigation regarding the utility of neurophysiological biomarkers for assessing cognitive outcomes of antipsychotic treatment in clinical trials and in early-phase drug development.

Original languageEnglish (US)
Pages (from-to)494-506
Number of pages13
JournalSchizophrenia Bulletin
Volume34
Issue number3
DOIs
StatePublished - May 2008

Fingerprint

Antipsychotic Agents
Schizophrenia
Risperidone
Saccades
Biomarkers
Therapeutics
Neuropsychological Tests
Executive Function
Reproducibility of Results
Cognition
Analysis of Variance
Healthy Volunteers
Multivariate Analysis
Clinical Trials
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Antipsychotics
  • Cognition
  • Neuropsychology
  • Oculomotor
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. / Hill, S. Kristian; Reilly, James L.; Harris, Margret S H; Khine, Tin; Sweeney, John A.

In: Schizophrenia Bulletin, Vol. 34, No. 3, 05.2008, p. 494-506.

Research output: Contribution to journalArticle

Hill, S. Kristian ; Reilly, James L. ; Harris, Margret S H ; Khine, Tin ; Sweeney, John A. / Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. In: Schizophrenia Bulletin. 2008 ; Vol. 34, No. 3. pp. 494-506.
@article{fb4c9c4280084092aedb2130eac47d6a,
title = "Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia",
abstract = "Cognitive enhancement has become an important target for drug therapies in schizophrenia. Treatment development in this area requires assessment approaches that are sensitive to procognitive effects of antipsychotic and adjunctive treatments. Ideally, new treatments will have translational characteristics for parallel human and animal research. Previous studies of antipsychotic effects on cognition have relied primarily on paper-and-pencil neuropsychological testing. No study has directly compared neurophysiological biomarkers and neuropsychological testing as strategies for assessing cognitive effects of antipsychotic treatment early in the course of schizophrenia. Antipsychotic-naive patients with schizophrenia were tested before treatment with risperidone and again 6 weeks later. Matched healthy participants were tested over a similar time period. Test-retest reliability, effect sizes of within-subject change, and multivariate/univariate analysis of variance were used to compare 3 neurophysiological tests (visually guided saccade, memory-guided saccade, and antisaccade) with neuropsychological tests covering 4 cognitive domains (executive function, attention, memory, and manual motor function). While both measurement approaches showed robust neurocognitive impairments in patients prior to risperidone treatment, oculomotor biomarkers were more sensitive to treatment-related effects on neurocognitive function than traditional neuropsychological measures. Further, unlike the pattern of modest generalized cognitive improvement suggested by neuropsychological measures, the oculomotor findings revealed a mixed pattern of beneficial and adverse treatment-related effects. These findings warrant further investigation regarding the utility of neurophysiological biomarkers for assessing cognitive outcomes of antipsychotic treatment in clinical trials and in early-phase drug development.",
keywords = "Antipsychotics, Cognition, Neuropsychology, Oculomotor, Schizophrenia",
author = "Hill, {S. Kristian} and Reilly, {James L.} and Harris, {Margret S H} and Tin Khine and Sweeney, {John A.}",
year = "2008",
month = "5",
doi = "10.1093/schbul/sbm112",
language = "English (US)",
volume = "34",
pages = "494--506",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia

AU - Hill, S. Kristian

AU - Reilly, James L.

AU - Harris, Margret S H

AU - Khine, Tin

AU - Sweeney, John A.

PY - 2008/5

Y1 - 2008/5

N2 - Cognitive enhancement has become an important target for drug therapies in schizophrenia. Treatment development in this area requires assessment approaches that are sensitive to procognitive effects of antipsychotic and adjunctive treatments. Ideally, new treatments will have translational characteristics for parallel human and animal research. Previous studies of antipsychotic effects on cognition have relied primarily on paper-and-pencil neuropsychological testing. No study has directly compared neurophysiological biomarkers and neuropsychological testing as strategies for assessing cognitive effects of antipsychotic treatment early in the course of schizophrenia. Antipsychotic-naive patients with schizophrenia were tested before treatment with risperidone and again 6 weeks later. Matched healthy participants were tested over a similar time period. Test-retest reliability, effect sizes of within-subject change, and multivariate/univariate analysis of variance were used to compare 3 neurophysiological tests (visually guided saccade, memory-guided saccade, and antisaccade) with neuropsychological tests covering 4 cognitive domains (executive function, attention, memory, and manual motor function). While both measurement approaches showed robust neurocognitive impairments in patients prior to risperidone treatment, oculomotor biomarkers were more sensitive to treatment-related effects on neurocognitive function than traditional neuropsychological measures. Further, unlike the pattern of modest generalized cognitive improvement suggested by neuropsychological measures, the oculomotor findings revealed a mixed pattern of beneficial and adverse treatment-related effects. These findings warrant further investigation regarding the utility of neurophysiological biomarkers for assessing cognitive outcomes of antipsychotic treatment in clinical trials and in early-phase drug development.

AB - Cognitive enhancement has become an important target for drug therapies in schizophrenia. Treatment development in this area requires assessment approaches that are sensitive to procognitive effects of antipsychotic and adjunctive treatments. Ideally, new treatments will have translational characteristics for parallel human and animal research. Previous studies of antipsychotic effects on cognition have relied primarily on paper-and-pencil neuropsychological testing. No study has directly compared neurophysiological biomarkers and neuropsychological testing as strategies for assessing cognitive effects of antipsychotic treatment early in the course of schizophrenia. Antipsychotic-naive patients with schizophrenia were tested before treatment with risperidone and again 6 weeks later. Matched healthy participants were tested over a similar time period. Test-retest reliability, effect sizes of within-subject change, and multivariate/univariate analysis of variance were used to compare 3 neurophysiological tests (visually guided saccade, memory-guided saccade, and antisaccade) with neuropsychological tests covering 4 cognitive domains (executive function, attention, memory, and manual motor function). While both measurement approaches showed robust neurocognitive impairments in patients prior to risperidone treatment, oculomotor biomarkers were more sensitive to treatment-related effects on neurocognitive function than traditional neuropsychological measures. Further, unlike the pattern of modest generalized cognitive improvement suggested by neuropsychological measures, the oculomotor findings revealed a mixed pattern of beneficial and adverse treatment-related effects. These findings warrant further investigation regarding the utility of neurophysiological biomarkers for assessing cognitive outcomes of antipsychotic treatment in clinical trials and in early-phase drug development.

KW - Antipsychotics

KW - Cognition

KW - Neuropsychology

KW - Oculomotor

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=46849095050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849095050&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbm112

DO - 10.1093/schbul/sbm112

M3 - Article

VL - 34

SP - 494

EP - 506

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -